Investors in Nektar Therapeutics Must Act Before Deadline for Class Action Claims

Nektar Therapeutics Investors: Act Before May 5, 2026 Deadline

Nektar Therapeutics (NASDAQ: NKTR) investors are being reminded by Faruqi & Faruqi, LLP, a leading national securities law firm, that the deadline for filing claims in a securities class action lawsuit is quickly approaching. The critical date is set for May 5, 2026, and it’s imperative for those who suffered losses during the period from February 26, 2025, to December 15, 2025, to consider their legal options.

The allegations stem from assertions that Nektar and its executives made misleading claims regarding the efficacy of their pivotal Phase 2b REZOLVE-AA trial. The lawsuit claims that the company failed to adhere to standard protocols, which compromised the integrity of the trial results. Specifically, it is alleged that misrepresentations were made when announcing the trial's topline results, which led to a substantial drop in Nektar's stock value when the truth was revealed.

In December 2025, Nektar announced that the trial for rezpegaldesleukin had not met statistical significance due to the involvement of ineligible patients, which caused its stock to plummet by over 7% in just a day. Investors who bought or acquired Nektar securities during the specified time frame are encouraged to reach out to Faruqi & Faruqi to discuss their potential claims.

Why File a Claim?

Taking action in this class action lawsuit might provide financial recompense to affected investors. A lead plaintiff, chosen from among the investors who sustained losses, will represent the entire class in court, and individuals can choose to be active participants or remain passive members of the class about which decisions are made. Importantly, one's ability to recover any compensation is not contingent upon whether or not they serve as the lead plaintiff.

Faruqi & Faruqi, which has a commendable track record of recovering hundreds of millions for investors, urges anyone with relevant information or inquiries regarding the Nektar case to connect with their legal team. The firm is adept at navigating the complexities of securities litigation and is committed to offering personalized legal consultation to all interested parties.

Contact Information

For those who wish to learn more about the ongoing legal proceedings against Nektar Therapeutics, they can visit www.faruqilaw.com/NKTR or get in touch with partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). Whether you are a shareholder, a whistleblower, or a former employee, your information could be invaluable in this case.

As the deadline draws near, it is essential for affected investors to act swiftly. Legal options and rights will not be prolonged beyond the set timeline, meaning prompt action could be critical in securing a just resolution.

Faruqi & Faruqi’s lawyers are standing by to provide necessary guidance on this matter. Be proactive in seeking justice and securing what may rightfully be yours. Don’t miss out on this opportunity to potentially recover losses sustained during a tumultuous period for Nektar Therapeutics.